A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders

Taro Kishi, Yuki Matsuda, Shinji Matsunaga, Tomohiko Mukai, Masatsugu Moriwaki, Hideaki Tabuse, Kiyoshi Fujita, Nakao Iwata

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: There has been no direct comparison of aripiprazole and blonanserin for schizophrenia treatment. We conducted a 24-week, rater-masked, randomized trial of aripiprazole (6-30 mg/d) vs blonanserin (4-24 mg/d) in schizophrenia patients who were not taking any antipsychotic medication for more than 2 weeks before enrollment (UMIN000011194). Methods: The primary outcome measure for efficacy was improvement of Positive and Negative Syndrome Scale (PANSS) total score at week 24. Secondary outcomes were PANSS subscale scores, 21-item Hamilton Rating Scale for Depression (HAMD-21) score, response rate, discontinuation rate, and individual adverse events. Results: Forty-four patients were recruited. The discontinuation rate was 86.4% in the aripiprazole group and 68.2% in the blonanserin treatment group. There was no significant difference in mean time to discontinuation between the groups. Although both treatment groups showed significant reductions in the PANSS total score, PANSS subscale scores, and HAMD-21 scores at week 24, the magnitudes of the changes did not differ between the groups. There were no significant differences in the incidences of adverse events including somnolence, extrapyramidal symptoms, prolactin-related adverse events, and weight change between the groups. Conclusion: Our results suggest similar efficacy and safety profiles of aripiprazole and blonanserin in the patients with schizophrenia. Double-blind controlled studies are needed to further explore the efficacy and safety of aripiprazole and blonanserin in schizophrenia.

Original languageEnglish
Pages (from-to)3041-3049
Number of pages9
JournalNeuropsychiatric Disease and Treatment
Volume12
DOIs
Publication statusPublished - 28-11-2016

Fingerprint

Schizophrenia
Therapeutics
Safety
Double-Blind Method
Prolactin
Antipsychotic Agents
Outcome Assessment (Health Care)
blonanserin
Aripiprazole
Depression
Weights and Measures
Incidence

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Kishi, Taro ; Matsuda, Yuki ; Matsunaga, Shinji ; Mukai, Tomohiko ; Moriwaki, Masatsugu ; Tabuse, Hideaki ; Fujita, Kiyoshi ; Iwata, Nakao. / A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders. In: Neuropsychiatric Disease and Treatment. 2016 ; Vol. 12. pp. 3041-3049.
@article{1a202d185bdf40fe88eec4762849724e,
title = "A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders",
abstract = "Objective: There has been no direct comparison of aripiprazole and blonanserin for schizophrenia treatment. We conducted a 24-week, rater-masked, randomized trial of aripiprazole (6-30 mg/d) vs blonanserin (4-24 mg/d) in schizophrenia patients who were not taking any antipsychotic medication for more than 2 weeks before enrollment (UMIN000011194). Methods: The primary outcome measure for efficacy was improvement of Positive and Negative Syndrome Scale (PANSS) total score at week 24. Secondary outcomes were PANSS subscale scores, 21-item Hamilton Rating Scale for Depression (HAMD-21) score, response rate, discontinuation rate, and individual adverse events. Results: Forty-four patients were recruited. The discontinuation rate was 86.4{\%} in the aripiprazole group and 68.2{\%} in the blonanserin treatment group. There was no significant difference in mean time to discontinuation between the groups. Although both treatment groups showed significant reductions in the PANSS total score, PANSS subscale scores, and HAMD-21 scores at week 24, the magnitudes of the changes did not differ between the groups. There were no significant differences in the incidences of adverse events including somnolence, extrapyramidal symptoms, prolactin-related adverse events, and weight change between the groups. Conclusion: Our results suggest similar efficacy and safety profiles of aripiprazole and blonanserin in the patients with schizophrenia. Double-blind controlled studies are needed to further explore the efficacy and safety of aripiprazole and blonanserin in schizophrenia.",
author = "Taro Kishi and Yuki Matsuda and Shinji Matsunaga and Tomohiko Mukai and Masatsugu Moriwaki and Hideaki Tabuse and Kiyoshi Fujita and Nakao Iwata",
year = "2016",
month = "11",
day = "28",
doi = "10.2147/NDT.S120786",
language = "English",
volume = "12",
pages = "3041--3049",
journal = "Neuropsychiatric Disease and Treatment",
issn = "1176-6328",
publisher = "Dove Medical Press Ltd.",

}

A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders. / Kishi, Taro; Matsuda, Yuki; Matsunaga, Shinji; Mukai, Tomohiko; Moriwaki, Masatsugu; Tabuse, Hideaki; Fujita, Kiyoshi; Iwata, Nakao.

In: Neuropsychiatric Disease and Treatment, Vol. 12, 28.11.2016, p. 3041-3049.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders

AU - Kishi, Taro

AU - Matsuda, Yuki

AU - Matsunaga, Shinji

AU - Mukai, Tomohiko

AU - Moriwaki, Masatsugu

AU - Tabuse, Hideaki

AU - Fujita, Kiyoshi

AU - Iwata, Nakao

PY - 2016/11/28

Y1 - 2016/11/28

N2 - Objective: There has been no direct comparison of aripiprazole and blonanserin for schizophrenia treatment. We conducted a 24-week, rater-masked, randomized trial of aripiprazole (6-30 mg/d) vs blonanserin (4-24 mg/d) in schizophrenia patients who were not taking any antipsychotic medication for more than 2 weeks before enrollment (UMIN000011194). Methods: The primary outcome measure for efficacy was improvement of Positive and Negative Syndrome Scale (PANSS) total score at week 24. Secondary outcomes were PANSS subscale scores, 21-item Hamilton Rating Scale for Depression (HAMD-21) score, response rate, discontinuation rate, and individual adverse events. Results: Forty-four patients were recruited. The discontinuation rate was 86.4% in the aripiprazole group and 68.2% in the blonanserin treatment group. There was no significant difference in mean time to discontinuation between the groups. Although both treatment groups showed significant reductions in the PANSS total score, PANSS subscale scores, and HAMD-21 scores at week 24, the magnitudes of the changes did not differ between the groups. There were no significant differences in the incidences of adverse events including somnolence, extrapyramidal symptoms, prolactin-related adverse events, and weight change between the groups. Conclusion: Our results suggest similar efficacy and safety profiles of aripiprazole and blonanserin in the patients with schizophrenia. Double-blind controlled studies are needed to further explore the efficacy and safety of aripiprazole and blonanserin in schizophrenia.

AB - Objective: There has been no direct comparison of aripiprazole and blonanserin for schizophrenia treatment. We conducted a 24-week, rater-masked, randomized trial of aripiprazole (6-30 mg/d) vs blonanserin (4-24 mg/d) in schizophrenia patients who were not taking any antipsychotic medication for more than 2 weeks before enrollment (UMIN000011194). Methods: The primary outcome measure for efficacy was improvement of Positive and Negative Syndrome Scale (PANSS) total score at week 24. Secondary outcomes were PANSS subscale scores, 21-item Hamilton Rating Scale for Depression (HAMD-21) score, response rate, discontinuation rate, and individual adverse events. Results: Forty-four patients were recruited. The discontinuation rate was 86.4% in the aripiprazole group and 68.2% in the blonanserin treatment group. There was no significant difference in mean time to discontinuation between the groups. Although both treatment groups showed significant reductions in the PANSS total score, PANSS subscale scores, and HAMD-21 scores at week 24, the magnitudes of the changes did not differ between the groups. There were no significant differences in the incidences of adverse events including somnolence, extrapyramidal symptoms, prolactin-related adverse events, and weight change between the groups. Conclusion: Our results suggest similar efficacy and safety profiles of aripiprazole and blonanserin in the patients with schizophrenia. Double-blind controlled studies are needed to further explore the efficacy and safety of aripiprazole and blonanserin in schizophrenia.

UR - http://www.scopus.com/inward/record.url?scp=85003441522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85003441522&partnerID=8YFLogxK

U2 - 10.2147/NDT.S120786

DO - 10.2147/NDT.S120786

M3 - Article

AN - SCOPUS:85003441522

VL - 12

SP - 3041

EP - 3049

JO - Neuropsychiatric Disease and Treatment

JF - Neuropsychiatric Disease and Treatment

SN - 1176-6328

ER -